Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.
FDA Grants Accelerated Approval to Liso-Cel for Relapsed/Refractory Follicular Lymphoma
Revisit the OncLive On Air Episodes From February 2024
Revisit Every OncLive On Air Episode From April 2024
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist